secwatch.observer — SEC 8-K summary
======================================

Issuer:     Beam Therapeutics Inc. (BEAM)
CIK:        0001745999
Form:       8-K
Filed at:   2025-05-06T23:59:59+00:00
Accession:  0000950170-25-063955
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Beam Q1 net loss $109.3M; cash $1.2B after $500M financing; clinical milestones hit
--------------------------------------------------------------------------------

- Net loss $109.3M ($1.24/share) vs $98.7M ($1.21/share) Q1 2024; R&D spend $98.8M.
- Cash $1.2B including $500M financing; runway into 2028.
- First patient dosed for BEAM-301 in GSDIa; IND cleared for BEAM-302 in AATD.
- BEAM-101 updated data accepted at EHA June 2025; aim to dose 30 SCD patients by mid-2025.
- BEAM-302 fourth cohort dosing started; further data expected H2 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1745999/000095017025063955/0000950170-25-063955-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1745999/000095017025063955/beam-20250506.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-063955

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer